MoneyWorks4Me

Glenmark Pharmaceuticals informs about media release

26 Oct 2021 Evaluate

Glenmark Pharmaceuticals has informed that it attached media release on October 26, 2021 titled ‘Glenmark becomes the first company to launch Remogliflozin + Vildagliptin + Metformin fixed dose combination, at an affordable price for adults with Type 2 Diabetes in India’.

The above information is a part of company’s filings submitted to BSE.

Peers
Company Name CMP
Sun Pharma. Inds. 1783.25
Dr. Reddys Labs. 1202.40
Cipla 1329.50
Lupin 2007.10
Zydus Lifesciences 1154.00
View more..